HomeHealthMedicineNew Research Finds Precision Medicine Has Reached a Global Tipping Point for...

New Research Finds Precision Medicine Has Reached a Global Tipping Point for Adoption

Life sciences leaders say time is finally right for healthcare systems, employers and governments to establish genome-informed clinical decision-making as the new standard of care

PHILADELPHIA, January 18, 2023 /PRNewswire/ — The Human Genome Project, completed nearly 20 years ago, promised an era of personalized healthcare. Now, new research shows that accurate prescribing using genetic testing has finally reached a global tipping point for acceptance.

Accurate prescribing using genetic testing has reached a global tipping point thanks to advances in the healthcare ecosystem

“We are now entering a new era where barriers have turned into blessings for PGx-enabled precision medicine.”

Published by Cambridge University Press, the peer-reviewed study– written by life science leaders on Corell Life Sciences-examines the maturation of critical factors required for the large-scale use of clinical genetics. These advancements pave the way to enable genome-informed clinical decision-making as the new standard of care.

“The stage is set for leaders around the world to change healthcare as we know it,” says co-author Scott Megil, President and CEO of Coriell Life Sciences, a global leader in precision medicine. “Studies have shown that using genetic information to provide more targeted therapeutic care significantly improves patient outcomes and reduces overall health care costs. used to determine whether drugs are likely to be unsafe… or ineffective for them specifically. We are now entering a new era where barriers have turned into blessings for PGx-enabled precision medicine.”

The study tracks and analyzes global readiness for large-scale implementation of PGx-enabled precision medicine based on five key factors:

  • Clinical utility: The capacity for meaningful clinical interpretations, recommendations and guidelines, based on existing research and clinical insight, to positively influence health outcomes

  • Laboratory Technology: Genotyping and sequencing technologies, and the standardization, regulation and efficient production of laboratory data and rapid delivery of results at large scale

  • User Acceptance: The extent to which patients, caregivers and payers understand, embrace and interact with genomic testing and the resulting insights

  • Deployment Models: The methods, processes and practices used to use PGx within healthcare systems

  • Economic value: The demonstrated real-world benefits of cost savings and patient health improvement directly attributable to the application of PGx-compatible precision medicine

Must Read
St. Mary's University Biology junior sets sights on medical school

The paper also examines other key factors driving PGx readiness, including:

The paper highlights that “genetically informed prescribing offers one of the few realistic mechanisms to effectively reduce the overall cost of the healthcare system while improving individual patient care and outcomes.” The authors conclude, “Now is the time for health care systems, employers and governments to work together and establish genome-informed clinical decision-making as the new standard of care.”

These findings are supported by the Coalition for Personalized Medicine (PMC), a group representing 220 member organizations made up of innovators, scientists, patients, providers and payers. PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and health systems.

“This research chronicles the industry’s significant progress toward the clinical use of population-scale pharmacogenomics and personalized medicine. Thanks to these advancements, which represent the work of multiple stakeholders, a new standard of care is finally within reach,” says Daryl PritchardPh.D., Senior Vice President, Science Policy, Personalized Medicine Coalition.

Jay G WohlgemuthMD, Chairman of the Board of the Personalized Medicine Coalition and SVP R&D and Chief Medical Officer for Quest Diagnostics, added: “Pharmacogenomics provides insights, based on a patient’s unique genetics, to help identify the best therapy upfront, reducing the risk of adverse side effects is reduced and wasted time and dollars on an ineffective treatment additional research showsWhen delivered as part of a consumer-facing medication management program that includes informatics and pharmacy services, pharmacogenomics is scalable for large populations and can provide actionable insights for most individuals. The field has matured to a stage where the many payers of health care services – including employers and health plans – can confidently embrace pharmacogenomics in their public health programs to optimize medical spending and outcomes.”

Must Read
Texas Tech, AAMW seek to create better animal adoption outcomes

For more information, read the full article,”Mature pharmacogenomics drive improvements and cost savings.”

About Coriell Life Sciences

Coriell Life Sciences (CLS) uses innovation in precision medicine to reduce healthcare costs and enable a healthier world. With scientific expertise spanning six decades, CLS bridges the gap between genetic knowledge and clinical application and provides the most comprehensive drug risk management program on the market. Visit coriell. com.

Media contact:
Pamela Carolo
For Coriell Life Sciences
pamela@caruolocommunications.com
484.574.2946

(PRNewsphoto/Coriell Life Sciences)

(PRNewsphoto/Coriell Life Sciences)

decision

decision

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-research-finds-precision-medicine-has-reached-a-global-tipping-point-for-adoption-301723906.html

SOURCE Coriell Life Sciences

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments